Zonisamide (Epilepsy) updated on 04-22-2025

Intrauterine deaths (as a whole or unspecified)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7506
R22454		 Meador (Zonisamide) (Controls exposed to Lamotrigine, sick), 2020 Fetal loss (Spontaneous miscarriages and fetal death) 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 1.25 [0.06;25.66] C
excluded (control group) 		0/13   3/113 3 13
ref
S7497
R22427		 Meador (Zonisamide) (Controls unexposed, disease free), 2020 Fetal loss (Spontaneous miscarriages and fetal death) 1st trimester prospective cohort unexposed, disease free excluded Adjustment: No 8.44 [0.16;444.34] C
excluded (control group) 		0/13   0/106 0 13
ref
S7502
R22442		 Meador (Zonisamide) (Controls unexposed, sick), 2020 Fetal loss (Spontaneous miscarriages and fetal death) 1st trimester prospective cohort unexposed, sick Adjustment: No 1.16 [0.02;62.85] C 0/13   0/15 0 13
ref
Total 1 studies 1.16 [0.02;62.85] 0 13
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Meador (Zonisamide) (Controls unexposed, sick), 2020Meador, 2020 1 1.16[0.02; 62.85]0130%ROB confusion: unclearROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: low0.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Zonisamide) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.16[0.02; 62.85]-13 -NAMeador (Zonisamide) (Controls unexposed, sick), 2020 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.16[0.02; 62.85]-13 -NAMeador (Zonisamide) (Controls unexposed, sick), 2020 1 Tags Adjustment   - No  - No 1.16[0.02; 62.85]-13 -NAMeador (Zonisamide) (Controls unexposed, sick), 2020 1 All studiesAll studies 1.16[0.02; 62.85]-13 -NAMeador (Zonisamide) (Controls unexposed, sick), 2020 10.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 7506, 7497

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 8.44[0.16; 444.34]-13 -NAMeador (Zonisamide) (Controls unexposed, disease free), 2020 1 unexposed, sick controlsunexposed, sick controls 1.16[0.02; 62.85]-13 -NAMeador (Zonisamide) (Controls unexposed, sick), 2020 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.25[0.06; 25.66]313 -NAMeador (Zonisamide) (Controls exposed to Lamotrigine, sick), 2020 10.510.01.0